Trivalent, Inactivated Influenza Virus Vaccine in Children With Sickle Cell Disease

Glezen, W. Paul; Glezen, Laurie S.; Alcorn, Roosevelt

doi:10.1001/archpedi.1983.02140370055018

Cited by 17 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study adds to the sparse literature on the safety of TIV, 13 or other types of influenza vaccine, 14,15 in children with sickle cell disease. The study design allowed us to identify sickle cell crisis events with individual-level electronic data and validate exposure and outcomes through detailed medical record review, a strength of the VSD.…”

Section: Discussionmentioning

confidence: 89%

Trivalent Inactivated Influenza Vaccine Is Not Associated With Sickle Cell Crises in Children

et al. 2012

View full text Add to dashboard Cite

Background and Objectives: Children with sickle cell disease are considered at high risk for complications from influenza infection and are recommended to receive annual influenza vaccination. However, data on the safety of influenza vaccination in children with sickle cell anemia are sparse. Methods: Using a retrospective cohort of children aged 6 months to 17 years in 8 managed care organizations that comprise the Vaccine Safety Datalink and who had a diagnosis of sickle cell anemia from 1999 to 2006, we conducted matched case-control and self-controlled case series studies to examine the association of trivalent inactivated influenza vaccination with hospitalization for sickle cell crisis in the 2 weeks after vaccination. Results: From an original pool of 1085 pediatric subjects with a diagnosis of sickle cell anemia, we identified 179 children with at least 1 sickle cell crisis during any influenza season (October 1–March 31). In the matched case-control study (matching on age category, gender, Vaccine Safety Datalink site, and season), the odds ratio of hospitalization for a crisis in vaccinated compared with unvaccinated children was not significant: 1.3 (95% confidence interval 0.8–2.2). In the self-controlled case series study of hospitalized cases, the incident rate ratio for hospitalization with sickle cell crisis in the 2 weeks after trivalent inactivated influenza vaccination was also not significant: 1.2 (95% confidence interval 0.75–1.95). Conclusions: This large cohort study did not find an association of influenza vaccination and hospitalization for sickle cell crises in children with sickle cell anemia.

show abstract

Section: Discussionmentioning

confidence: 89%

Trivalent Inactivated Influenza Vaccine Is Not Associated With Sickle Cell Crises in Children

et al. 2012

View full text Add to dashboard Cite

show abstract

“…74 In 1 small study of children with sickle cell disease, HAI response to TIV immunization was adequate. 75 …”

Section: Immunogenicity Of Tivmentioning

confidence: 99%

Technical Report: Reduction of the Influenza Burden in Children

Rennels¹,

Meissner²

2002

Pediatrics

View full text Add to dashboard Cite

ABSTRACT. Epidemiologic studies have shown that children of all ages with certain chronic conditions, such as asthma, and otherwise healthy children younger than 24 months (6 through 23 months) are hospitalized for influenza and its complications at high rates similar to those experienced by the elderly. Annual influenza immunization is already recommended for all children 6 months and older with high-risk conditions. By contrast, influenza immunization has not been recommended for healthy young children. To protect children against the complications of influenza, increased efforts are needed to identify and recall high-risk children. In addition, immunization of children between 6 through 23 months of age and their close contacts is now encouraged to the extent feasible. Children younger than 6 months may be protected by immunization of their household contacts and out-of-home caregivers. The ultimate goal is universal immunization of children 6 to 24 months of age.

show abstract

“…1 In one study, SCD was associated with a 56-fold increased risk of influenza-related hospitalization. 2 Yet, despite its effectiveness, 3,4 most children with SCD do not receive the influenza vaccine yearly. 5 Recognition of the influenza A virus of swine origin (H1N1) in March 2009 6 caused heightened concern.…”

Section: Introductionmentioning

confidence: 99%

Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease

Strouse

Reller²,

Bundy³

et al. 2010

Blood

View full text Add to dashboard Cite

Influenza causes excess morbidity in sickle cell disease (SCD). H1N1 pandemic influenza has been severe in children. To compare H1N1 with seasonal influenza in SCD (patients younger than 22), we reviewed medical records (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)). We identified 123 cases of laboratory-confirmed influenza (94 seasonal, 29 H1N1). Those with seasonal influenza were younger (median 4.4 vs 8.7 years old, P ‫؍‬ .006) and had less asthma (24% vs 56%, P ‫؍‬ .002). Those with H1N1 influenza more often had acute chest syndrome (ACS; 34% vs 13%, P ‫؍‬ .01) and required intensive care (17% vs 3%, P ‫؍‬ .02), including mechanical ventilation (10% vs 0%, P ‫؍‬ .02). In multivariate analysis, older age (odds ratio [OR] 1.1 per year, P ‫؍‬ .04) and H1N1 influenza (OR 3.0, P ‫؍‬ .04) were associated with ACS, and older age (OR 1.1 per year, P ‫؍‬ .02) and prior ACS (OR 3.3 per episode in last year, P < .006) with intensive care. Influenza, especially H1N1, causes critical illness in SCD and should be prevented. IntroductionInfluenza causes disproportionate morbidity in sickle cell disease (SCD), an inherited hemoglobinopathy affecting 1 in 2500 children in the United States. 1 In one study, SCD was associated with a 56-fold increased risk of influenza-related hospitalization. 2 Yet, despite its effectiveness, 3,4 most children with SCD do not receive the influenza vaccine yearly. 5 Recognition of the influenza A virus of swine origin (H1N1) in March 2009 6 caused heightened concern. Case series of H1N1 influenza in SCD have reported severe illness, with 10 in 21 children and 2 in 2 adults developing acute chest syndrome (ACS). 7,8 To assess the relative severity of pandemic H1N1 versus seasonal influenza in SCD, we performed a comprehensive analysis at our institution. Methods Study populationWe identified patients aged Ͻ 22 years with SCD and influenza by searching for SCD and respiratory virus testing from September 1, 1993, to April 30, 2007, in the discharge and billing databases of Johns Hopkins Hospital (JHH). From May 1, 2007, to December 10, 2009, we also prospectively identified patients with SCD and influenza admitted to the pediatric hematology service or seen in the pediatric emergency department at JHH. We reviewed clinical records to identify influenza vaccination and administrative records to estimate the number of patients aged Ͻ 22 years with SCD seen at JHH. Additional information appears in supplemental data (available on the Blood Web site; see the Supplemental Materials link at the top of the online article). DefinitionsWe defined influenza as laboratory-confirmed influenza A or B and ACS as a new pulmonary infiltrate involving Ն 1 complete lung segment with fever (Ͼ 38.5°C), tachypnea, cough, wheezing, or chest pain. 9 We defined severe pain as pain requiring Ͼ 2 doses of opiates and asthma exacerbation as bronchodilator-treated wheezing. Diagnosis of influenzaInfluenza was detected by rapid antigen-based test (immunochromatograp...

show abstract

Trivalent, Inactivated Influenza Virus Vaccine in Children With Sickle Cell Disease

Cited by 17 publications

References 11 publications

Trivalent Inactivated Influenza Vaccine Is Not Associated With Sickle Cell Crises in Children

Trivalent Inactivated Influenza Vaccine Is Not Associated With Sickle Cell Crises in Children

Technical Report: Reduction of the Influenza Burden in Children

Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease

Contact Info

Product

Resources

About